T&D Pharma Gmbh company information, Employees & Contact Information

TD Cowen resumes BioCryst Pharma stock coverage with Buy rating Investing.com

BioCryst Pharma (BCRX) Reinstated as 'Buy' by TD Cowen with $30 PT | BCRX Stock News GuruFocus

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference EyePoint Pharmaceuticals

Analysing the Threat of Pharmacy Benefit Manager Reform – Ahead of the Curve TD Securities

TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales Insider Monkey

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says Reuters

TD Cowen Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $100 富途牛牛

TD Cowen Maintains a Buy on Royalty Pharma (RPRX) Insider Monkey

TD Cowen 30th Annual Drug Pricing Survey Results TD Securities

TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns Investing.com

TD Cowen reiterates Buy rating on Royalty Pharma stock, citing strong metrics Investing.com

TD Cowen maintains Buy rating on Ascendis Pharma stock Investing.com

BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales Investing.com

Merck to acquire Verona Pharma stock for $107 per ADS, TD Cowen downgrades Investing.com

TD Cowen maintains buy rating for Regeneron Pharma stock Investing.com

Ascendis Pharma stock price target raised by TD Cowen on Yorvipath momentum Investing.com

PMV Pharmaceuticals stock rating reiterated at Buy by TD Cowen Investing.com

TD Cowen spots top pharma events with $1B+ potential in 2025 Investing.com

Milestone Pharmaceuticals stock rating cut to hold by TD Cowen Investing.com

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA FinancialContent

GLP-1 Market: The Pipeline Expands – AHEAD OF THE CURVE TD Securities

New drugs mean higher prices — and a big year for Big Pharma qz.com

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com Investing.com Canada

What will the new 15% ceiling on pharma tariffs mean for Mayo? Mayo TD speaks to CNN The Mayo News

"Local Pharmaceutical Jobs under threat by new US Tariffs" says local TD Ocean FM

The Current State of the Biopharma Development Industry TD Securities

Deploying Private Equity in Biotech TD Securities

Stocks that will see action today: Sun TV, Keynes Tech, Diageo, TD Power, Sai Life, Privi Speciality Chef, Hindustan Power, Natco Pharma, Crisil, UFlex, Mastek, ITD Cementation, Krishna Phoschem, Choice International, Gallantt Spat, Ashoka Buildcon BusinessLine

Carnie Wilson Teams with Neurocrine Biosciences for TD Awareness Campaign Pharmaceutical Executive

Non-invasive detection of protein aggregation in biopharmaceuticals using TD-NMR and MRI ScienceDirect.com

Pfizer could shift overseas production to US if Trump's pharma tariffs take hold, CEO says Fierce Pharma

Breaking Through Pain: New Targets and Opportunities – AHEAD OF THE CURVE TD Securities

Novo, Lilly, AZ lead pharma growth through 2030, TD Cowen says Fierce Pharma

As Austedo, Ajovy and Uzedy gain steam, Teva banks on $5B-plus in 2030 innovative drug sales Fierce Pharma

FDA approves Teva's AUSTEDO XR for TD and HD chorea Pharmaceutical Technology

TD Cowen Research Themes 2025 TD Securities

Neurocrine holds on to branded tardive dyskinesia push with help from Wilson Phillips star Fierce Pharma

Time domain NMR for polymorphism characterization: Current status and future perspectives ScienceDirect.com

Evoke Pharma to Present New Data Comparing Tardive GlobeNewswire

With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors Fierce Pharma

Trump signs order to reign in prescription drug ads on TV TheDesk.net

Distributors, PBMs & Biopharma: Unlocking Biosimilar Value TD Securities

TD Cowen holds Buy on Milestone Pharmaceuticals stock, expects peak sales of $441M Investing.com

H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) Insider Monkey

CNS Drug Developer Supernus Pharmaceuticals Announces Triple Conference Schedule for September 2025 Stock Titan

Neurocrine backs push for increased awareness, diagnosis of tardive dyskinesia Fierce Pharma

Lagging rival Neurocrine, Teva preps ad campaign in tardive dyskinesia Fierce Pharma

Doctors are coming around to Teva's Austedo as TD drugs get more play: analyst Fierce Pharma

Teva takes on Neurocrine with TD nod for Austedo Fierce Pharma

Ingrezza-maker Neurocrine brings tardive dyskinesia awareness to the tube Fierce Pharma

8 Stocks To Buy For Short-term: Analysts recommend 3 largecap, 5 midcap stocks for 2 weeks; Swiggy, Balrampur Chini Mills on the list Zee Business